ES2233036T3 - Composicion farmaceutica que comprende factor viii y liposomas neutros. - Google Patents

Composicion farmaceutica que comprende factor viii y liposomas neutros.

Info

Publication number
ES2233036T3
ES2233036T3 ES99916022T ES99916022T ES2233036T3 ES 2233036 T3 ES2233036 T3 ES 2233036T3 ES 99916022 T ES99916022 T ES 99916022T ES 99916022 T ES99916022 T ES 99916022T ES 2233036 T3 ES2233036 T3 ES 2233036T3
Authority
ES
Spain
Prior art keywords
fviii
pharmaceutical composition
protein
colloidal particles
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99916022T
Other languages
English (en)
Spanish (es)
Inventor
Moshe Baru
Liliana Bar
Israel Nur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opperbas Holding BV
Original Assignee
Opperbas Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opperbas Holding BV filed Critical Opperbas Holding BV
Application granted granted Critical
Publication of ES2233036T3 publication Critical patent/ES2233036T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES99916022T 1998-04-27 1999-04-23 Composicion farmaceutica que comprende factor viii y liposomas neutros. Expired - Lifetime ES2233036T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12422498 1998-04-27
IL12422498 1998-04-27

Publications (1)

Publication Number Publication Date
ES2233036T3 true ES2233036T3 (es) 2005-06-01

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99916022T Expired - Lifetime ES2233036T3 (es) 1998-04-27 1999-04-23 Composicion farmaceutica que comprende factor viii y liposomas neutros.

Country Status (12)

Country Link
US (2) US6593294B1 (enExample)
EP (1) EP1079805B1 (enExample)
JP (1) JP4545928B2 (enExample)
AT (1) ATE283034T1 (enExample)
AU (1) AU747391B2 (enExample)
BR (1) BR9909978A (enExample)
CA (1) CA2329768C (enExample)
DE (1) DE69922189T2 (enExample)
ES (1) ES2233036T3 (enExample)
MX (1) MXPA00010241A (enExample)
PT (1) PT1079805E (enExample)
WO (1) WO1999055306A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7718160B2 (en) * 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
DE602004013769D1 (de) * 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
US20050069578A1 (en) * 2003-08-05 2005-03-31 Balasubramanian Sathyamangalam V. Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
JP4966018B2 (ja) * 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007117469A2 (en) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
CN105838699A (zh) * 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
PL2299953T3 (pl) 2008-07-14 2017-10-31 Polypid Ltd Kompozycja nośnika leku o przedłużonym uwalnianiu
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
IN2012DN00570A (enExample) 2009-07-14 2015-06-12 Polypid Ltd
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
WO2011084610A1 (en) 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
AU2015283822B2 (en) 2014-07-02 2019-10-03 CSL Behring Lengnau AG Modified von willebrand factor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
SG11201708755WA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
US11246832B2 (en) * 2016-06-28 2022-02-15 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Also Published As

Publication number Publication date
DE69922189D1 (de) 2004-12-30
DE69922189T2 (de) 2005-11-10
EP1079805B1 (en) 2004-11-24
EP1079805A1 (en) 2001-03-07
MXPA00010241A (es) 2004-09-06
AU3441499A (en) 1999-11-16
JP2002512947A (ja) 2002-05-08
ATE283034T1 (de) 2004-12-15
PT1079805E (pt) 2005-03-31
WO1999055306A1 (en) 1999-11-04
JP4545928B2 (ja) 2010-09-15
CA2329768A1 (en) 1999-11-04
US6593294B1 (en) 2003-07-15
BR9909978A (pt) 2000-12-26
US20030134778A1 (en) 2003-07-17
AU747391B2 (en) 2002-05-16
US6930087B2 (en) 2005-08-16
CA2329768C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
ES2233036T3 (es) Composicion farmaceutica que comprende factor viii y liposomas neutros.
Baru et al. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy
Scott et al. Therapy of von Willebrand disease
ES2259674T3 (es) Liposomas de encapsulacion de farmacos anticancerosos y utilizacion de los mismos en el tratamiento de tumores malignos.
US20240366732A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
ES2307009T3 (es) Composicion farmaceutica que contiene proteinas y/o polipeptidos y particulas coloidales.
US20030232075A1 (en) Compositions for producing factor Xa
US11484499B2 (en) Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
Fatouros et al. Recombinant factor VIII SQ—stability of VIII: C in homogenates from porcine, monkey and human subcutaneous tissue
IL139053A (en) Pharmaceutical composition comprising factor VIII and neutral colloidal particles
US20240358801A1 (en) Modified colloidal particles for use in the treatment of haemophilia a
Castaman et al. Haematological care of the haemophilic patient
Lisman et al. Mechanism of action of recombinant activated Factor VII
KR20240042134A (ko) A형 혈우병 치료용 변형된 콜로이드 입자